Agenda - Day 3 | TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

8:00am - 8:10am

Registration and Coffee

Plenary Session

Showing 1 of 1 Streams

Plenary Sessions

8:10am - 8:15am

Chairperson’s Remarks

8:15am - 8:45am

Modulation of Host Immunity in the Airways with Interferon Lambda Encoding mRNA

Christian Plank, PhD - Chief Technology Officer, Ethris GmbH

8:45am - 9:15am

Strategies for mRNA Analytics

Simon Klenk, PhD - Director RNA Analytics, RNA Biochemistry, BioNTech SE

9:15am - 9:45am

Fine Tuning a PCR based mRNA Manufacturing Platform for each mRNA Sequence

Aditi Mehta, PhD - Associate Director, Head of mRNA Process & Deliver, Merck KGaA

9:45am - 10:15am

Lipid Nanoparticles to Enable Clinical Development of mRNA-based Therapeutics

Ying Tam, Ph.D. - Chief Scientific Officer, Acuitas Therapeutics

10:15am - 10:55am

Networking Refreshment Break with Poster and Exhibit Viewing

Concurrent Conference Tracks

Showing 2 of 2 Streams

Track #1

Track #2

10:55am - 11:00am

Chairperson’s Remarks

11:00am - 11:30am

Preclinical Data for STK-002, an Antisense Oligonucleotide Being Developed for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

Shobha Ravipaty, PhD - Director, Stoke Therapeutics

11:30am - 12:00pm

Discovery and Delivery of Oligonucleotide Therapeutics

Jayaprakash Nair, PhD - Vice President, Research, Chemistry and Delivery Science, Alnylam Pharmaceuticals

12:00pm - 12:30pm

From Bench to Bedside: Development of a GalXC-Plus siRNA, DCR-STAT3, for Immunotherapy in Refractory Cancer Patients

Jennifer Lockridge, PhD - VP, Dicerna TRU Early Development, Novo Nordisk

10:55am - 11:00am

Chairperson’s Remarks

11:00am - 11:30am

Protein-based Nano-capsules for Delivery of Therapeutic RNAs Across the Blood-Brain-Barrier

Ekkehard Leberer, PhD - Scientific Advisor, Neuway Pharma

11:30am - 12:00pm

Redefining Non-viral Delivery for Novel Genomic Medicines with Tissue-targeted Lipid Nanoparticle (ttLNP) Platform

Kate Zhang, Ph.D. - Chief Scientific Officer, Hopewell Therapeutics

12:00pm - 12:30pm

Tuning Lipid Nanoparticles for Specific Applications

Ed Yaworski - Chief Technology Officer, Genevant Sciences Corp

12:30pm - 1:40pm

Networking Luncheon with Poster and Exhibit Viewing

Showing 2 of 2 Streams

Track #1

Track #2

1:40pm - 1:45pm

Chairperson’s Remarks

1:45pm - 2:15pm

Examples of Antisense Oligonucleotides that Target the Immunosuppressive Tumor Microenvironment for Treatment of Cancer

Frank Jaschinski, Ph.D. - Chief Scientific Officer, Secarna Pharmaceuticals

2:15pm - 2:45pm

CIVI 008: An Orally Active LNA Drug Against PCSK9

Henrik Oerum, PhD - Founder and Chief Scientific Officer, CiVi Biopharma Inc.

2:45pm - 3:15pm

Development of TTX-MC138, a First-in-Class miRNA-10b-Targeted Therapeutic Against Metastatic Cancers of Multiple Primary Disease Origins

Zdravka Medarova, PhD - Founder and Chief Technology Officer, TransCode Therapeutics

1:40pm - 1:45pm

Chairperson’s Remarks

1:45pm - 2:15pm

Gate2Brain Shuttles, Going Beyond the Transport of Small Molecules

Meritxell Teixidó, PhD - CEO and CSO, Gate2Brain

2:15pm - 2:45pm

Control Strategy Set-Up for Efficient & Safe Large Scale Peptide Manufacturing Process

El Djouhar Rekaï, PhD - Head of Peptide Process Development & Manufacturing, PolyPeptide Group

2:45pm - 3:15pm

In-line Monitoring Method Integrating Flow Chemistry for Peptide/Nucleotide Synthesis

Pengyu Xu, Ph.D. - President and Representative Director, SynCrest Inc.

3:15pm - 3:45pm

Networking Refreshment Break with Poster and Exhibit Viewing

Showing 2 of 2 Streams

Track #1

Track #2

3:45pm - 4:15pm

Chimeric PN-containing Oligonucleotides Yield Exon Skipping in Preclinical Models and Boys with Duchenne Muscular Dystrophy

Elizabeth Wagner, Ph.D. - Director, Biology, Wave Life Sciences

4:15pm - 4:45pm

Key Elements of a Well Composed Nonclinical Section of an IND Application

Emily Place, PhD - Senior Consultant Nonclinical, Biologics Consulting

4:45pm - 5:15pm

GalAhead™: A Proprietary GalNAc-RNAi Therapeutic Platform to Downregulate Single and Multiple Genes

Jimmy Weterings, PhD - Senior Director, Head of Technology Development, Sirnaomics

3:45pm - 4:15pm

Peptide CMC Strategies

Stephane Varray, PhD - Director, Global Peptides Platform, CordenPharma International

4:15pm - 4:45pm

Biocatalysis for Green Manufacturing of Amino Acids

Christina Boville, PhD - Co-founder & CEO, Aralez Bio

4:45pm - 5:15pm

Individualised Cancer Vaccines: Developing a High-throughput cGMP Manufacturing Philosophy

Alaric Desmarchelier, PhD - Business Development Manager - Peptides, Almac Group

5:15pm - 5:20pm

Close of Conference

SAVINGS DEADLINE EXPIRES IN:

SAVINGS DEADLINE EXPIRES IN:

Day 3Thursday, 21 March 2024

Day 3Thursday, 21 March 2024

Get the Latest Event Updates